Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Legislation
Appropriations report directs the US FDA to offer the faster assessment and allow reliance on prior data submitted for applications caught in the transition from drug to biologic regulation.
Pelosi is moving forward with a draconian plan to limit US prices to an international benchmark. For now, the “bill” is a three-page outline subject to considerable legislative drafting – and so extreme as to rule out bipartisan compromise for the time being.
House bill in the works to deter brand product switches should specify what behavior would be unacceptable, legal experts testify at congressional hearing.
Former US FDA commissioner Scott Gottlieb makes a case for regional or national risk pools to ensure pediatric patients get timely access to gene therapy like the upcoming treatments for sickle cell disease.
Pharmaceutical companies will have a better idea of the conditions under which a supplementary protection certificate can be granted after an advocate general of the European court explained how a new legal test established last year should be used. However, lawyers caution that the opinion still leaves some aspects to be clarified.
The most important thing to know about a draft version of the House Democratic leadership’s proposed drug price negotiation plan is that it is still just a draft – not the draft – much less a bill that could pass the Democratic controlled House, to say nothing of the GOP controlled Senate.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.